NDA 202344 · Radius
Binosto
Alendronate Sodium · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Feb 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Mar 12, 2012
Approved uses
1
Original approval plus efficacy supplements
Registered trials
181
59 Phase 3, 7 recruiting
FAERS reports
32,875
27,174 serious, 5,614 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 6, 2026.
BINOSTO is a bisphosphonate indicated for: Treatment of osteoporosis in postmenopausal women ( 1.1 ) Treatment to increase bone mass in men with osteoporosis ( 1.2 ) Limitation of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.3 ) 1.1 Treatment of Osteoporosis in Postmenopausal Women BINOSTO effervescent tablet 70 mg is indicated for the treatment of osteoporosis in postmenopausal women. For the treatment of osteoporosis, alendronate sodium increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [See Clinical Studies (14.1) .] 1.2 Treatment to Increase Bone Mass in Men With Osteoporosis BINOSTO is indicated for treatment to increase bone mass in men with osteoporosis [see Clinical Studies (14.2) ] . 1.3 Important Limitations of Use The optimal duration of use has not been determined. The safety and effectiveness of BINOSTO for the treatment of osteoporosis are based on clinical data of four years duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.
Mechanism: Animal studies have indicated the following mode of action. At the cellular level, alendronate shows preferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active resorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [ 3 H]alendronate in bone showed about 10-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 12, 2012 Original approval · Type 3 - New Dosage Form ReviewSummary ReviewLabel
1 products under this application
- BINOSTO · ALENDRONATE SODIUM EQ 70MG BASE · TABLET, EFFERVESCENT, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Alendronate" as an intervention, any sponsor and status, largest first.
- Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With OsteoporosisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01631214 · 4,093 participants · Start May 4, 2012 · Primary completion Feb 27, 2017
Drug: Romosozumab; Alendronate and 2 more · For: Postmenopausal Women With Osteoporosis
Sites: Birmingham, Alabama; Peoria, Arizona; Phoenix, Arizona · 316 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02604836 · 1,711 participants · Start Jun 2004 · Primary completion Apr 2006
Drug: Ibandronate · For: Postmenopausal Osteoporosis
Sites: Birmingham, Alabama; Columbiana, Alabama; Huntsville, Alabama · 142 sites in all
- A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without FracturesPivotal-lookingRecruiting
Odense University HospitalAcademic, hospital or other
NCT06864130 · 1,400 participants (planned) · Start Feb 21, 2025 · Primary completion Mar 1, 2029
Drug: Alendronate 70mg weekly · For: Osteoporosis in Post-menopausal Women
Sites: Aalborg, Denmark; Copenhagen, Denmark; Esbjerg, Denmark · 8 sites in all
- Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With OsteoporosisPivotal-lookingCompleted
Daiichi Sankyo Co., Ltd.Daiichi Sankyo (DSNKY)
NCT00680953 · 1,262 participants · Start May 2008 · Primary completion Jun 2012
Drug: Denosumab; Placebo and 1 more · For: Osteoporosis
Sites: Fukuoka, Japan; Osaka, Japan; Sapporo, Japan · 4 sites in all
- A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00330460 · 1,189 participants · Start May 2006 · Primary completion Nov 2007
Drug: Alendronate; Denosumab · For: Osteoporosis; Osteopenia
- Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With OsteoporosisPivotal-lookingCompleted
Radius Health, Inc.Industry
NCT01657162 · 1,139 participants · Start Nov 20, 2012 · Primary completion Oct 3, 2016
Drug: Alendronate · For: Postmenopausal Osteoporosis
Sites: Lakewood, Colorado; Hialeah, Florida; Bethesda, Maryland · 25 sites in all
- FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00398931 · 1,099 participants · Start Feb 1998 · Primary completion Oct 2003
Drug: MK0217, alendronate sodium / Duration of Treatment : 5 Years; Comparator : placebo (unspecified) /Duration of Treatment : 5 Years · For: Osteoporosis, Postmenopausal
- A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00092014 · 1,053 participants · Start Sep 1, 2002 · Primary completion Apr 1, 2004
Drug: Alendronate; Risedronate 35 mg and 2 more · For: Postmenopausal Osteoporosis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pain6,008
- fatigue5,923
- drug ineffective5,675
- arthralgia5,348
- rheumatoid arthritis5,157
- rash4,780
- abdominal discomfort4,675
- alopecia4,656
- femur fracture4,636
- arthropathy4,418
- systemic lupus erythematosus4,406
- pemphigus4,386
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 716 |
| 2005 | 692 |
| 2006 | 372 |
| 2007 | 412 |
| 2008 | 679 |
| 2009 | 830 |
| 2010 | 1,051 |
| 2011 | 1,549 |
| 2012 | 3,085 |
| 2013 | 1,575 |
| 2014 | 1,026 |
| 2015 | 872 |
| 2016 | 814 |
| 2017 | 880 |
| 2018 | 1,081 |
| 2019 | 1,136 |
| 2020 | 1,568 |
| 2021 | 2,362 |
| 2022 | 2,636 |
| 2023 | 1,972 |
| 2024 | 2,968 |
| 2025 | 2,864 |
| 2026 | 1,735 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Binosto (Alendronate Sodium)
2024 spending
$459K
Beneficiaries
283
1,123 claims
Per beneficiary
$1,621
$73.81 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,165,135 |
| 2021 | $711,236 |
| 2022 | $699,155 |
| 2023 | $539,470 |
| 2024 | $458,704 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Ayers C, Kansagara D, Lazur B, et al. · Ann Intern Med 2023 · Systematic Review, Network Meta-Analysis
- Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Saag KG, Petersen J, Brandi ML, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Comparative Study
- Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis.
Liu Q, Chen D, Ye Z, et al. · Medicine (Baltimore) 2020 · Meta-Analysis, Systematic Review
- The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Moshi MR, Nicolopoulos K, Stringer D, et al. · Calcif Tissue Int 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Alendronate modulates cytokine responses in healthy young individuals after BCG vaccination.
Bulut O, Kilic G, Debisarun PA, et al. · Immunol Lett 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ye Z, Silverberg SJ, Sreekanta A, et al. · J Bone Miner Res 2022 · Meta-Analysis, Systematic Review
Sponsor: Radius
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.